Get the Stockscreener App
11.23
1.66%
-0.19
Immunic Inc stock is traded at $11.23, with a volume of 250.67K.
It is down -1.66% in the last 24 hours and down -30.07% over the past month.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.
See More
Previous Close:
$11.42
Open:
$11.43
24h Volume:
250.67K
Relative Volume:
1.22
Market Cap:
$153.23M
Revenue:
-
Net Income/Loss:
$-104.29M
P/E Ratio:
-1.8615
EPS:
-6.0329
Net Cash Flow:
$-81.45M
1W Performance:
-14.34%
1M Performance:
-30.07%
6M Performance:
-4.02%
1Y Performance:
+41.38%
1-Day Range:
$11.04
$11.46
1-Week Range:
$11.04
$13.28
52-Week Range:
$5.062
$17.43
Immunic Inc Stock (IMUX) Company Profile
Name
Immunic Inc
Sector
Industry
Phone
(332) 255-9818
Address
1200 AVENUE OF THE AMERICAS, NEW YORK
Compare IMUX vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMUX
Immunic Inc
|
11.23 | 155.82M | 0 | -104.29M | -81.45M | -6.0329 |
VRTX
Vertex Pharmaceuticals Inc
|
519.51 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.74 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
990.54 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
146.69 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
205.11 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immunic Inc Stock (IMUX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-17-26 | Initiated | Stifel | Buy |
| Apr-15-26 | Downgrade | D. Boral Capital | Buy → Hold |
| Mar-24-26 | Initiated | Guggenheim | Buy |
| Nov-07-25 | Initiated | Roth Capital | Buy |
| Sep-29-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-25-25 | Initiated | William Blair | Outperform |
| Nov-25-24 | Initiated | H.C. Wainwright | Buy |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Aug-27-24 | Initiated | B. Riley Securities | Buy |
| Oct-21-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-19-22 | Resumed | H.C. Wainwright | Buy |
| Apr-15-21 | Initiated | Aegis Capital | Buy |
| Mar-24-21 | Initiated | JMP Securities | Mkt Outperform |
| Oct-02-20 | Initiated | SVB Leerink | Outperform |
| Aug-26-20 | Initiated | Piper Sandler | Overweight |
| Aug-07-20 | Resumed | ROTH Capital | Buy |
| Jul-20-20 | Initiated | BMO Capital Markets | Outperform |
| Jun-05-20 | Initiated | Wedbush | Outperform |
| May-11-20 | Initiated | H.C. Wainwright | Buy |
| Mar-25-20 | Initiated | ROTH Capital | Buy |
| Jul-11-19 | Initiated | Chardan Capital Markets | Buy |
View All
Immunic Inc Stock (IMUX) Latest News
Immunic announces resignation of director Duane Nash and board size reduction By Investing.com - Investing.com Australia
Why Did IMUX Stock Surge 33% Pre-Market Today? - Stocktwits
Immunic Director Dr. Duane Nash Resigns; Board Cut to Nine Members - minichart.com.sg
Form 8K Immunic Inc For: 11 September By Investing.com - Investing.com South Africa
Immunic announces resignation of director Duane Nash and board size reduction - Investing.com
Dr. Duane Nash resigns from Immunic board; board reduced to nine members - TradingView
symbol__ Stock Quote Price and Forecast - CNN
Immunic director Duane Nash resigns, board shrinks to nine members - Bitget
H.C. Wainwright reiterates Immunic stock rating on MS drug progress By Investing.com - Investing.com Nigeria
Immunic, Inc. (IMUX) Presents at EFMC Medicinal Chemistry 2026 BaselSlideshow (NASDAQ:IMUX) 2026-09-10 - Seeking Alpha
IMUX Reiterated by Wedbush -- Price Target Maintained at $45 - GuruFocus
Why Is Immunic (NASDAQ:IMUX) Advancing Its MS Drug Program? - Kalkine Media
Stifel reiterates Immunic stock rating on MS drug potential By Investing.com - Investing.com Canada
Stifel reiterates Immunic stock rating on MS drug potential - investing.com
IMUX Reiterates by HC Wainwright & Co. -- Price Target Maintained at $22 - GuruFocus
Immunic, Inc. R&D Day Transcript - GuruFocus
IMUX: Pivotal Phase 3 data for vidofludimus calcium in relapsing MS expected by end of 2026 - TradingView
Immunic (NASDAQ: IMUX) plans Sept. 9 relapsing MS R&D webinar - stocktitan.net
Immunic hosts RMS R&D Day webinar, presents vidofludimus calcium program and forward-looking plans - TradingView
Immunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026 - PR Newswire
Immunic Inc (NASDAQ: IMUX) Share Price, IMUX Stock News, IMUX Share Price & Updates - Kalkine
Immunic lines up three July investor events in Boston and SF - stocktitan.net
Small cap wrap: Immunic, Midnight Sun Mining, Purepoint Uranium... - proactiveinvestors.com.au
Immunic to host virtual R&D day on relapsing MS ahead of Phase 3 trial results - Pluang
Immunic to host virtual relapsing MS R&D Day on September 9 - Yahoo Finance
EQS-News: Immunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026boerse.de - boerse.de
Immunic names Chitrang Davé chief data and digital officer - thepharmaletter.com
Immunic Appoints Chitrang Davé as Chief Data and Digital Officer - Investing News Network
Immunic appoints Chitrang Davé as chief data and digital officer - Yahoo Finance
Immunic: Potent Under-The-Radar MS Lineup Set For A Rerating (NASDAQ:IMUX) - Seeking Alpha
Long term debt to total assets ratio of Immunic, Inc. – HAM:10V - TradingView
Discontinued operations of Immunic, Inc. – HAM:10V - TradingView
Wedbush initiates Immunic stock with Outperform rating By Investing.com - Investing.com Australia
IMUX Initiates Coverage On Wedbush -- Rating Set to Outperform - GuruFocus
Wedbush initiates Immunic stock with Outperform rating - Investing.com
Renaissance Technologies LLC Invests $1.02 Million in Immunic, Inc. $IMUX - MarketBeat
Immunic (NASDAQ:IMUX) Upgraded to "Hold" at Wall Street Zen - MarketBeat
Immunic Inc. (IMUX) Pulls Back 3.14% to $16.06 as Key Support at $15.26 Comes into FocusCall Flow Alert - Vinanet
Immunic, Inc. (IMUX): OrbiMed entities disclose 5.3% and 2.8% equity holdings - Stock Titan
Nantahala Capital discloses 7.47% Immunic (IMUX) stake in Schedule 13G/A - Stock Titan
Immunic (IMUX): Commodore Capital discloses 9.9% stake capped by warrant limits - Stock Titan
Can Immunic (IMUX) Climb 163.03% to Reach the Level Wall Street Analysts Expect? - Yahoo Finance
Immunic Inc Stock (IMUX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.75%
3.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):